SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Apr 27, 2026–
Encoded Therapeutics Inc., a scientific-stage genetic medicines company, this present day launched its participation in the 29 th Annual Meeting of the American Society of Gene & Cell Treatment (ASGCT), taking net site Also can simply 11–15, 2026, in Boston, Massachusetts. Encoded will most up to the moment three abstracts, including one oral presentation in the Presidential Symposium and two scientific posters, demonstrating the breadth of its vector engineering platform all by draw of severe neurological concerns.
The Presidential Symposium oral presentation will focal point on ETX101, Encoded’s precision gene-regulation therapy being developed as a one-time remedy for sufferers with SCN1A + Dravet syndrome. ETX101 is designed to elongate SCN1A expression selectively within GABAergic inhibitory neurons, offering the aptitude for disease modification.
The poster shows will consist of preclinical data on Encoded’s original regulatory component, NociPro, which targets distress-sensing nociceptive neurons for the remedy of chronic distress stipulations, and an intravenously delivered vectorized miRNA draw designed to unsilence UBE3A for the remedy of Angelman syndrome.
“We’re extremely proud to most up to the moment our most up to the moment POLARIS data at this prestigious ASGCT platform, showcasing ETX101’s likely to pork up seizure preserve a watch on and basically rescue discovering out and cognitive pattern in adolescents residing with Dravet syndrome,” said Sal Rico, M.D., Ph.D., Chief Medical Officer of Encoded. “Along with our poster shows, these findings underscore our vector engineering draw and its likely to raise precision one‑time genetic medicines for neurological concerns.”
Presentation Particulars
Oral Presentation: Security and Efficacy of ETX101, an Investigational AAV9-essentially based Gene Treatment for SCN1A + Dravet Syndrome: Length in-between Results from the POLARIS Section 1/2 Scientific Trials
Session: Trendy Session: Presidential Symposium
Field: Level to Hall B1 (Level to Level)
Date and Time: Wednesday, Also can simply 13, 2026; 2:26 PM – 2:37 PM ET
Poster Presentation: NociPro: A Recent Modality-Agnostic Promoter Platform for Proper Cellular Focused on of Nociceptor Sensory Neurons in Gene Treatment for Persistent Bother
Abstract Quantity: 1312
Field: Poster Hall
Date and Time: Tuesday, Also can simply 12, 2026; 5:00 PM – 6:30 PM ET
Poster Presentation: An Experimental Intravenous AAV-miRNA-essentially based Intention Achieves Big Neuronal Transduction and UBE3A Unsilencing for the Treatment of Angelman Syndrome
Abstract Quantity: 1468
Field: Poster Hall
Date and Time: Tuesday, Also can simply 12, 2026; 5:00 PM – 6:30 PM ET
About Encoded Therapeutics
Encoded Therapeutics is a scientific-stage biotechnology company growing one-time precision genetic medicines for severe monogenic and fashioned neurological concerns. The corporate’s vector engineering platform permits extremely centered and cell-form-selective preserve a watch on of gene expression in the mind and peripheral worried gadget, allowing potent and valid modulation of disease-connected genes to tackle underlying disease biology. Encoded’s close‑to‑close innovation engine—spanning discovery, pattern, and in‑apartment GMP manufacturing—creates a streamlined path to come a diversified pipeline of one‑time therapies all by draw of a enormous fluctuate of neurological stipulations. Encoded is driven by a mission to meaningfully pork up the lives of sufferers and households plagued by devastating neurological concerns. For more data, please focus on with www.encoded.com.
Leer provide model on businesswire.com:https://www.businesswire.com/recordsdata/dwelling/20260427756983/en/
CONTACT: Investors/Enterprise Style
Jennifer Gorzelany
Lori Rosen
KEYWORD: CALIFORNIA MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL CLINICAL TRIALS
SOURCE: Encoded Therapeutics, Inc.
Copyright Enterprise Wire 2026.
PUB: 04/27/2026 04:30 PM/DISC: 04/27/2026 04:32 PM
http://www.businesswire.com/recordsdata/dwelling/20260427756983/en
